William Sharfman

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

Svetomir N. Markovic, Susan M. Geyer, Fitzroy W. Dawkins et al. · Cancer · 2005 · 131 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.

Ronald M. Bukowski, William Sharfman, S. Murthy et al. · PubMed · 1991 · 102 citations

Medicine, Immunology, Oncology +17

A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, ± dacarbazine (DTIC) in patients with metastatic melanoma (MM)

Peter Hersey, Jeff Sosman, Steven O’Day et al. · Journal of Clinical Oncology · 2005 · 55 citations

Medicine, Oncology, Pharmacology +11

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

Catherine S. Grasso, Jennifer Tsoi, Mykola Onyshchenko et al. · Cancer Cell · 2020 · 53 citations · Full text

Life Sciences, Immunology, Oncology +14

Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.

Barry L. Gause, Mario Sznol, William C. Kopp et al. · Journal of Clinical Oncology · 1996 · 32 citations

Medicine, Oncology, Pharmacology +17